Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
IAS 2011: New Studies Add Evidence that PrEP Reduces HIV Infection Risk
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 13 July 2011 00:00
- Written by Liz Highleyman
Pre-exposure prophylaxis (PrEP) using tenofovir/emtricitabine (the drugs in Truvada) lowers the risk of HIV transmission among heterosexuals, according to 2 African studies to be presented next week at the 6th International AIDS Society Conference of HIV Pathogenesis, Treatment and Prevention (IAS 2011).
Women's PrEP Study Halted due to Disappointing Findings
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 22 April 2011 14:40
- Written by HIVandHepatitis.com
A trial of Truvada pre-exposure prophylaxis for women in Africa was discontinued this week after an interim review found that the study was unlikely to show a reduction in HIV infections.
CDC Issues Guidance for Truvada Pre-exposure Prophylaxis
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 01 February 2011 00:00
- Written by Liz Highleyman
The U.S. Centers for Disease Control and Prevention (CDC) this week issued interim guidance regarding the use of tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) against HIV infection. The guidelines, published in the January 28, 2011, Morbidity and Mortality Weekly Report, note the limitations of the recent iPrEx trial and recommend PrEP only for gay/bisexual men with "substantial, ongoing, high risk" for acquiring HIV.
CROI 2011: Researchers Report Further Findings from iPrEx PrEP Trial
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Monday, 07 March 2011 20:49
- Written by Paul Dalton
Investigators presented further details of findings from the ground-breaking iPrEx trial this week at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston. With longer follow-up, pre-exposure prophylaxis (PrEP) using tenofovir/emtricitabine (Truvada) continued to have a protective effect against HIV acquisition, but signs of mild bone loss raise potential concerns about safety.
U.S. Advocates Offer Strategies for Pre-exposure Prophylaxis to Prevent HIV Infection
- Details
- Category: HIV Prevention
- Published on Tuesday, 14 December 2010 20:32
- Written by Liz Highleyman
The National PrEP Committee, a new coalition of treatment advocates, policy experts, and others, has released a report on strategies for using pre-exposure prophylaxis, or taking antiretroviral drugs as a way to prevent HIV infection. Recently published data from the iPrEx trial showed that daily use of tenofovir/emtricitabine (Truvada) reduced the risk of HIV acquisition by 44% among gay and bisexual men, but many questions remain regarding adherence, cost, and other potential concerns.
More Articles...
- Truvada PrEP Cuts HIV Infection by 44% among Gay/Bisexual Men in Worldwide Study
- AIDS 2010: Oral Tenofovir for Pre-exposure Prophylaxis Appears Safe and Does Not Discourage Safer Sex
- Antiretroviral Therapy for HIV Prevention Could Lead to Drug Resistance If Not Carefully Implemented
- Pre-Exposure Prophylaxis with Tenofovir plus Emtricitabine Prevents HIV Infection in
Web Design and Development by